Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 23:11:659135.
doi: 10.3389/fonc.2021.659135. eCollection 2021.

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies

Mike Wenzel  1   2 , Felix Preisser  1 , Benedikt Hoeh  1 , Maria Schroeder  1 , Christoph Würnschimmel  2   3 , Thomas Steuber  3 , Hans Heinzer  3 , Severine Banek  1 , Marit Ahrens  4 , Andreas Becker  1 , Pierre I Karakiewicz  2 , Felix K H Chun  1 , Luis A Kluth  1 , Philipp Mandel  1
Affiliations

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies

Mike Wenzel et al. Front Oncol. .

Abstract

Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.

Material and methods: Of 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR <12, 12-18, 18-24, and >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.

Results: Median follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR <12 months, 18.1% for 12-18 months, 15.2% for 18-24 months, and 25.5% for >24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR <12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months, and >24 months, in that order (p<0.001). After multivariable adjustment, a 4.07-, 3.31-, and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months, and <12 months patients, relative to TTCR >24 months (all p<0.05). Conversely, OS after development of mCRPC was not influenced by TTCR stratification (all p>0.05).

Conclusion: Patients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients.

Keywords: CRPC; castration resistance; metastatic prostate cancer; mortality; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier plot illustrating overall survival in metastatic hormone-sensitive prostate cancer (mHSPC) patients diagnosed between 2013-2020, stratified according to time to castration resistance (TTCR). The follow-up starts from the beginning of the therapy in mHSPC. M, Months.
Figure 2
Figure 2
Kaplan-Meier plot illustrating overall survival in metastatic castration resistance prostate cancer (mCRPC) patients diagnosed between 2013-2020, stratified according to the time to castration resistance (TTCR). M, Months.
See this image and copyright information in PMC

References

    1. Eeles RA, Olama AAA, Benlloch S, Saunders J, Leongamornlert DA, Tymrakiewicz M, et al. . Identification of 23 New Prostate Cancer Susceptibility Loci Using the iCOGS Custom Genotyping Array. Nat Genet (2013) 45(4):385–91, 391e1-2. 10.1038/ng.2560 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. 10.3322/caac.21551 - DOI - PubMed
    1. Malvezzi M, Carioli G, Bertuccio P, Lev F, La Veccia C, Negri E. European Cancer Mortality Predictions for the Year 2019 With Focus on Breast Cancer. Ann Oncol (2019) 30(5):781–7. 10.1093/annonc/mdz051 - DOI - PubMed
    1. Mottet N, Cornford P, Van den Bergh RCN, Lev F, La Veccia C, Negri E, et al. . Eau - EANM - ESTRO - ESUR - SIOG. Guidelines on Prostate Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. (2020).
    1. Patrikidou A, Loriot Y, Eymard J-C, Albiges L, Massard C, Ileana E, et al. . Who Dies From Prostate Cancer? Prostate Cancer Prostatic Dis (2014) 17(4):348–52. 10.1038/pcan.2014.35 - DOI - PubMed